Get the Stockscreener App
5.825
6.05%
-0.375
After Hours:
5.82
-0.005
-0.09%
Protara Therapeutics Inc stock is traded at $5.825, with a volume of 729.47K.
It is down -6.05% in the last 24 hours and down -10.38% over the past month.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
See More
Previous Close:
$6.20
Open:
$6.02
24h Volume:
729.47K
Relative Volume:
0.64
Market Cap:
$312.15M
Revenue:
-
Net Income/Loss:
$-52.90M
P/E Ratio:
-4.0359
EPS:
-1.4433
Net Cash Flow:
$-48.79M
1W Performance:
+0.95%
1M Performance:
-10.38%
6M Performance:
+84.92%
1Y Performance:
+60.47%
1-Day Range:
$5.81
$6.15
1-Week Range:
$5.645
$6.56
52-Week Range:
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
Name
Protara Therapeutics Inc
Sector
Industry
Phone
646-844-0337
Address
345 PARK AVENUE SOUTH, NEW YORK, NY
Compare TARA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.825 | 332.24M | 0 | -52.90M | -48.79M | -1.4433 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Apr-16-25 | Initiated | Scotiabank | Sector Outperform |
| Mar-14-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-10-23 | Resumed | Guggenheim | Buy |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Feb-17-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Cowen | Outperform |
| Jul-29-20 | Initiated | Guggenheim | Buy |
View All
Protara Therapeutics Inc Stock (TARA) Latest News
Protara gains as JP Morgan starts at overweight - Seeking Alpha
Protara Therapeutics (NASDAQ:TARA) Now Covered by JPMorgan Chase & Co. - MarketBeat
JP Morgan Initiates Coverage on TARA with Overweight Rating and $27 PT | TARA Stock News - GuruFocus
Breakout Watch: Can Protara Therapeutics Inc beat the S P 5002025 Sector Review & Weekly High Return Opportunities - baoquankhu1.vn
Millennium group reports 2.76M shares in Protara (TARA) — 5.1% stake - Stock Titan
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf - Yahoo Finance
TARA PE Ratio & Valuation, Is TARA Overvalued - Intellectia AI
TARA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Protara Therapeutics Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
TARA Should I Buy - Intellectia AI
Protara Therapeutics, Inc. (TARA) Presents at 2026 ASCO Genitourinary Cancers SymposiumSlideshow - Seeking Alpha
TARA: TARA-002 advances in NMIBC and LM with promising data and expanding regulatory pathways - TradingView
667, L.P. resale reported for TARA (NASDAQ: TARA) — 26,755 shares - Stock Titan
Protara Therapeutics (TARA) Receives a Buy from Piper Sandler - The Globe and Mail
Protara Therapeutics (TARA) to Release Earnings on Wednesday - MarketBeat
Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU - MarketBeat
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Protara Therapeutics (TARA) and Kiniksa Pharmaceuticals (KNSA) - The Globe and Mail
Protara Therapeutics (TARA) Shares Drop 22% After Interim Trial Data - GuruFocus
[144] Protara Therapeutics, Inc. SEC Filing - Stock Titan
Protara reports interim results from bladder cancer trial By Investing.com - Investing.com South Africa
Protara falls after trial data for lead asset (TARA:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Bladder phase II sinks Protara, LMs phase III wins for Palvella - bioworld.com
Protara Highlights Strong Phase 2 Data for TARA-002 - TipRanks
TARA: TARA-002 shows strong efficacy and safety in NMIBC, with high CR rates and durable responses - TradingView
Protara posts positive interim ADVANCED-2 results; TARA-002 shows 68% 6‑month CR in BCG‑unresponsive NMIBC - TradingView
What's Going On With Protara Therapeutics Stock Tuesday?Protara Therapeutics (NASDAQ:TARA) - Benzinga
TARA-002 results send Protara shares upwards - The Pharma Letter
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data? - Stocktwits
Protara Therapeutics stock tumbles on trial data release By Investing.com - Investing.com South Africa
Protara Therapeutics (TARA) Shares Promising Phase 2 Trial Resul - GuruFocus
Protara Therapeutics stock tumbles on trial data release - Investing.com
Protara Therapeutics (TARA) Shares Promising Phase 2 Trial Results - GuruFocus
Protara reports interim results from bladder cancer trial - Investing.com
TARA-002 demonstrates 68% complete response rate at six months in BCG-unresponsive non-muscle invasive bladder cancer - marketscreener.com
TARA-002 Demonstrates 68% Complete Response Rate at Six - GlobeNewswire
Protara's Experimental Bladder Cancer Drug Shows Encouraging Results - Bitget
Piper Sandler Reaffirms Their Buy Rating on Protara Therapeutics (TARA) - The Globe and Mail
Should I average down on Protara Therapeutics Inc. stockBuy Signal & Fast Exit Strategy with Risk Control - mfd.ru
Protara Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Muscle Invasive Bladder Cancer Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | CG Oncology, Pfizer, UroGen Pharma, Janssen R&D, Protara Therapeutics, Binhui Biopharmaceutical - Barchart.com
Published on: 2026-02-19 10:51:48 - baoquankhu1.vn
TARA Technical Analysis & Stock Price Forecast - Intellectia AI
ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards - The Chronicle-Journal
Published on: 2026-02-16 18:05:35 - baoquankhu1.vn
Published on: 2026-02-16 20:21:04 - baoquankhu1.vn
Protara Therapeutics (NASDAQ:TARA) Given Buy Rating at HC Wainwright - Defense World
Protara Therapeutics (TARA): HC Wainwright Reiterates Buy Rating | TARA Stock News - GuruFocus
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Why Protara Therapeutics Inc. stock is seen as undervaluedExit Point & Real-Time Stock Movement Alerts - mfd.ru
Protara Therapeutics Inc Stock (TARA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):